newsfilter
← Latest News
GlobeNewswire·

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health